These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 34302953)
1. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India. Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study. Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958 [TBL] [Abstract][Full Text] [Related]
3. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199 [TBL] [Abstract][Full Text] [Related]
4. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia. Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM Front Immunol; 2021; 12():633323. PubMed ID: 34790190 [TBL] [Abstract][Full Text] [Related]
5. SARS COV-2- IgG antibodies in blood donors in pandemic - A game changer for policy makers. Mahapatra S Transfus Clin Biol; 2022 Feb; 29(1):11-15. PubMed ID: 34653615 [TBL] [Abstract][Full Text] [Related]
6. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations. Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484 [TBL] [Abstract][Full Text] [Related]
8. Progression and Predictors of SARS-CoV-2 Antibody Seroreactivity In US Blood Donors. Vassallo RR; Dumont LJ; Bravo MD; Hazegh K; Kamel H Transfus Med Rev; 2021 Jul; 35(3):8-15. PubMed ID: 34376289 [TBL] [Abstract][Full Text] [Related]
9. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation. Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776 [TBL] [Abstract][Full Text] [Related]
11. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors. Hirani R; Hoad V; Gosbell IB; Irving DO Transfusion; 2022 Feb; 62(2):292-297. PubMed ID: 34936102 [TBL] [Abstract][Full Text] [Related]
12. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384 [TBL] [Abstract][Full Text] [Related]
13. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial. Romera Martínez I; Avendaño-Solá C; Villegas Da Ros C; Bosch Llobet A; García Erce JA; González Fraile MI; Guerra Domínguez L; Vicuña Andrés I; Anguita Velasco J; González Rodríguez VP; Contreras E; Urcelay Uranga S; Pajares Herraiz ÁL; Jimenez-Marco T; Ojea Pérez AM; Arroyo Rodríguez JL; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Bueno Cabrera JL; Duarte RF Vox Sang; 2024 Jan; 119(1):27-33. PubMed ID: 37986640 [TBL] [Abstract][Full Text] [Related]
14. Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors. Martin MC; Jimenez A; Ortega N; Parrado A; Page I; Gonzalez MI; Blanco-Peris L PLoS One; 2022; 17(2):e0264124. PubMed ID: 35202394 [TBL] [Abstract][Full Text] [Related]
15. The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection. Fazeli A; Sharifi S; Mohammadi S; Bahraini M; Arabkhazaeli A; Jelveh N; Eshghi P Transfus Apher Sci; 2022 Apr; 61(2):103302. PubMed ID: 34774440 [TBL] [Abstract][Full Text] [Related]
16. Utility of COVID-19 Seropositive Plasma as Convalescent Plasma: An Immune and Neutralization Antibody Seroprevalence Analysis in Blood Donors for Future Potential Pandemic Readiness. Jain A; Negi G; Kaur D; S V; Saxena V Cureus; 2024 Mar; 16(3):e57149. PubMed ID: 38681329 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area. Jain S; Garg K; Tran SM; Rask IL; Tarczon M; Nandi V; Kessler DA; Strauss D; Sachais BS; Yazdanbakhsh K; Rehmani S; Luchsinger L; Shi PA Transfusion; 2021 Aug; 61(8):2374-2383. PubMed ID: 33904609 [TBL] [Abstract][Full Text] [Related]
18. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations. Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595 [TBL] [Abstract][Full Text] [Related]
19. Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan. Suzuki T; Asai Y; Ide S; Fukuda S; Tanaka A; Shimanishi Y; Takahashi K; Terada M; Sato L; Sato M; Inada M; Yamada G; Miyazato Y; Akiyama Y; Nomoto H; Nakamoto T; Nakamura K; Togano T; Morioka S; Kinoshita-Iwamoto N; Saito S; Kutsuna S; Ohmagari N J Infect Chemother; 2022 Feb; 28(2):206-210. PubMed ID: 34756573 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines. Dodd RY; Spencer BR; Xu M; Foster GA; Saá P; Brodsky JP; Stramer SL Transfus Med Rev; 2021 Jul; 35(3):1-7. PubMed ID: 34373145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]